Author: Mercy Heimbach
Physeon Announces Enrollment of First Patient in US “VIVA” Trial for Veinplicity

SCHAFFHAUSEN, Switzerland, Nov. 12, 2018 (GLOBE NEWSWIRE) — Physeon GmbH (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced that the first patient has been enrolled in its “VIVA” (Veinplicity for Improved Venous Access) Trial in the United States for the Veinplicity® Device.

Novavax Expands Leadership with Several Key Management Promotions

GAITHERSBURG, Md., Nov. 12, 2018 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX) today announced several management promotions.  “We are pleased to announce several key management promotions to further support the advancement of our company and its lead clinical programs into commercial stage,” said Stanley Erck, President and Chief Executive Officer of Novavax, Inc. “These individuals have […]

How Corbus Uses Synthetic Cannabinoids to Fight Diseases
| Bloomberg

Yuval Cohen, Corbus Pharmaceuticals chief executive officer, discusses how the company is combating autoimmune diseases with Bloomberg’s Ed Hammond on “Bloomberg Markets: The Close.”